| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
|
Medicine details |
|
| Medicine name | apixaban (Eliquis®) |
| Formulation | film-coated tablet |
| Reference number | 477 |
| Indication | Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, with one or more risk factors, such as prior stroke or transient ischaemic attack; age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II) |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd/Pfizer Ltd |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/12/2012 |
| NICE guidance | |